scholarly journals Amelioration of Citrobacter rodentium proliferation in early stage of infection in mice by pre-treatment with Lactobacillus brevis KB290 and verification using in vivo bioluminescence imaging

2016 ◽  
pp. fnw254
Author(s):  
Naoko Waki ◽  
Yuki Kuwabara ◽  
Yuko Yoshikawa ◽  
Hiroyuki Suganuma ◽  
Hiroyuki Koide ◽  
...  
Keyword(s):  
Bioluminescence Imaging ◽  
Early Stage ◽  
Lactobacillus Brevis ◽  
Citrobacter Rodentium ◽  
In Vivo Bioluminescence Imaging ◽  
Pre Treatment

scholarly journals In Vivo Bioluminescence Imaging of the Murine Pathogen Citrobacter rodentium

2006 ◽  
Vol 74 (9) ◽  
pp. 5391-5396 ◽  
Author(s):  
Siouxsie Wiles ◽  
Karen M. Pickard ◽  
Katian Peng ◽  
Thomas T. MacDonald ◽  
Gad Frankel
Keyword(s):  
Blood Circulation ◽  
Bioluminescence Imaging ◽  
Citrobacter Rodentium ◽  
Oxygen Requirement ◽  
E Coli ◽  
In Vivo Bioluminescence Imaging ◽  
Colonization Dynamics ◽  
A Site ◽  
Colonic Environment

ABSTRACT Citrobacter rodentium is a natural mouse pathogen related to enteropathogenic and enterohemorrhagic Escherichia coli. We have previously utilized bioluminescence imaging (BLI) to determine the in vivo colonization dynamics of C. rodentium. However, due to the oxygen requirement of the bioluminescence system and the colonic localization of C. rodentium, in vivo localization studies were performed using harvested organs. Here, we report the detection of bioluminescent C. rodentium and commensal E. coli during colonization of the gastrointestinal tract in intact living animals. Bioluminescence was dependent on intact blood circulation, suggesting that the colonic environment is not anaerobic but nanaerobic. In addition, BLI revealed that C. rodentium colonizes the rectum, a site previously unreported for this pathogen.

The Antitumor Effects of Britanin on Hepatocellular Carcinoma Cells and its Real-Time Evaluation by In Vivo Bioluminescence Imaging

2020 ◽  
Vol 20 (9) ◽  
pp. 1147-1156
Author(s):  
Hanrui Li ◽  
GeTao Du ◽  
Lu Yang ◽  
Liaojun Pang ◽  
Yonghua Zhan
Keyword(s):  
Hepatocellular Carcinoma ◽  
Western Blot ◽  
Blot Analysis ◽  
Tumor Size ◽  
Hepg2 Cells ◽  
Western Blot Analysis ◽  
Bioluminescence Imaging ◽  
Antitumor Effects ◽  
In Vivo Bioluminescence Imaging

Background: Hepatocellular carcinoma is cancer with many new cases and the highest mortality rate. Chemotherapy is the most commonly used method for the clinical treatment of hepatocellular carcinoma. Natural products have become clinically important chemotherapeutic drugs due to their great potential for pharmacological development. Many sesquiterpene lactone compounds have been proven to have antitumor effects on hepatocellular carcinoma. Objective: Britanin is a sesquiterpene lactone compound that can be considered for the treatment of hepatocellular carcinoma. The present study aimed to investigate the antitumor effect of britanin. Methods: BEL 7402 and HepG2 cells were used to study the cytotoxicity and antitumor effects of britanin. Preliminary studies on the nuclear factor kappa B pathway were conducted by western blot analysis. A BEL 7402-luc subcutaneous tumor model was established for the in vivo antitumor studies of britanin. In vivo bioluminescence imaging was conducted to monitor changes in tumor size. Results: The results of the cytotoxicity analysis showed that the IC50 values for britanin in BEL 7402 and HepG2 cells were 2.702μM and 6.006μM, respectively. The results of the colony formation demonstrated that the number of cells in a colony was reduced significantly after britanin treatment. And the results of transwell migration assays showed that the migration ability of tumor cells was significantly weakened after treatment with britanin. Tumor size measurements and staining results showed that tumor size was inhibited after britanin treatment. The western blot analysis results showed the inhibition of p65 protein expression and reduced the ratio of Bcl-2/Bax after treatment. Conclusion: A series of in vitro and in vivo experiments demonstrated that britanin had good antitumor effects and provided an option for hepatocellular carcinoma treatment.

In Vivo Bioluminescence Imaging of Transplanted Islets and Early Detection of Graft Rejection

2006 ◽  
Vol 81 (10) ◽  
pp. 1421-1427 ◽  
Author(s):  
Xiaojuan Chen ◽  
Xiaomin Zhang ◽  
Courtney S. Larson ◽  
Marshall S. Baker ◽  
Dixon B. Kaufman
Keyword(s):  
Early Detection ◽  
Graft Rejection ◽  
Bioluminescence Imaging ◽  
In Vivo Bioluminescence Imaging

scholarly journals An Advanced Preclinical Mouse Model for Acute Myeloid Leukemia Using Patients' Cells of Various Genetic Subgroups and In Vivo Bioluminescence Imaging

PLoS ONE ◽  
2015 ◽  
Vol 10 (3) ◽  
pp. e0120925 ◽  
Author(s):  
Binje Vick ◽  
Maja Rothenberg ◽  
Nadine Sandhöfer ◽  
Michela Carlet ◽  
Cornelia Finkenzeller ◽  
...  
Keyword(s):  
Acute Myeloid Leukemia ◽  
Mouse Model ◽  
Myeloid Leukemia ◽  
Bioluminescence Imaging ◽  
In Vivo Bioluminescence Imaging ◽  
Acute Myeloid

Real-time in vivo bioluminescence imaging of drug-induced oxidative stress

2016 ◽  
Vol 258 ◽  
pp. S234
Author(s):  
S. Seyed Forootan ◽  
F. Mutter ◽  
J. Clarke ◽  
A. Kipar ◽  
K. Park ◽  
...  
Keyword(s):  
Oxidative Stress ◽  
Real Time ◽  
Bioluminescence Imaging ◽  
Drug Induced ◽  
In Vivo Bioluminescence Imaging

Use of in vivo bioluminescence imaging to predict hepatic tumor burden in mice

2004 ◽  
Vol 120 (2) ◽  
pp. 249-255 ◽  
Author(s):  
Shiva Sarraf-Yazdi ◽  
Jing Mi ◽  
Mark W. Dewhirst ◽  
Bryan M. Clary
Keyword(s):  
Bioluminescence Imaging ◽  
Tumor Burden ◽  
Hepatic Tumor ◽  
In Vivo Bioluminescence Imaging

scholarly journals Upregulation of miR181a/miR212 Improves Myogenic Commitment in Murine Fusion-Negative Rhabdomyosarcoma

2021 ◽  
Vol 12 ◽  
Author(s):  
Enrico Pozzo ◽  
Nefele Giarratana ◽  
Gabriele Sassi ◽  
Merve Elmastas ◽  
Theo Killian ◽  
...  
Keyword(s):  
Skeletal Muscle ◽  
Pluripotent Stem Cell ◽  
Bioluminescence Imaging ◽  
Clinical Applications ◽  
Imaging Analysis ◽  
Epigenetic Memory ◽  
Novel Mirna ◽  
Molecular Machinery ◽  
Pre Treatment

Fusion-negative rhabdomyosarcoma (FN-RMS) is the most common soft tissue sarcoma of childhood arising from undifferentiated skeletal muscle cells from uncertain origin. Currently used therapies are poorly tumor-specific and fail to tackle the molecular machinery underlying the tumorigenicity and uncontrolled proliferation of FN-RMS. We and other groups recently found that microRNAs (miRNA) network contributes to myogenic epigenetic memory and can influence pluripotent stem cell commitments. Here, we used the previously identified promyogenic miRNAs and tailored it to the murine FN-RMS. Subsequently, we addressed the effects of miRNAs in vivo by performing syngeneic transplant of pre-treated FN-RMS cell line in C57Bl/6 mice. miRNA pre-treatment affects murine FN-RMS cell proliferation in vivo as showed by bioluminescence imaging analysis, resulting in better muscle performances as highlighted by treadmill exhaustion tests. In conclusion, in our study we identified a novel miRNA combination tackling the anti-myogenic features of FN-RMS by reducing proliferation and described novel antitumorigenic therapeutic targets that can be further explored for future pre-clinical applications.

Sign in / Sign up

Export Citation Format

Share Document